DE60324427D1 - Verfahren zur modulation der tubulindeacetylase-aktivität - Google Patents

Verfahren zur modulation der tubulindeacetylase-aktivität

Info

Publication number
DE60324427D1
DE60324427D1 DE60324427T DE60324427T DE60324427D1 DE 60324427 D1 DE60324427 D1 DE 60324427D1 DE 60324427 T DE60324427 T DE 60324427T DE 60324427 T DE60324427 T DE 60324427T DE 60324427 D1 DE60324427 D1 DE 60324427D1
Authority
DE
Germany
Prior art keywords
tubulindeacetylase
modulating
activity
ribavirin
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60324427T
Other languages
English (en)
Inventor
Eric Verdin
Brian J North
Scott M Ulrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE60324427D1 publication Critical patent/DE60324427D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60324427T 2002-05-20 2003-05-20 Verfahren zur modulation der tubulindeacetylase-aktivität Expired - Lifetime DE60324427D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38221802P 2002-05-20 2002-05-20
PCT/US2003/015813 WO2003099210A2 (en) 2002-05-20 2003-05-20 Methods of modulating tubulin deacetylase activity

Publications (1)

Publication Number Publication Date
DE60324427D1 true DE60324427D1 (de) 2008-12-11

Family

ID=29584377

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324427T Expired - Lifetime DE60324427D1 (de) 2002-05-20 2003-05-20 Verfahren zur modulation der tubulindeacetylase-aktivität

Country Status (8)

Country Link
US (2) US7351542B2 (de)
EP (2) EP1514105B1 (de)
AT (1) ATE412771T1 (de)
AU (1) AU2003229329B2 (de)
CA (1) CA2485988C (de)
DE (1) DE60324427D1 (de)
ES (1) ES2318131T3 (de)
WO (1) WO2003099210A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1506313B1 (de) * 2002-05-23 2011-01-26 The Regents of The University of California Verfahren zum Auswählen von Modulatoren der mitochondrialen NAD-abhängigen Deacetylase, SIRT3
JP2006520796A (ja) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
US20060084135A1 (en) * 2003-07-01 2006-04-20 Howitz Konrad T Compositions for manipulating the lifespan and stress response of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
AU2004312072B2 (en) 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2005072408A2 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Treating a viral disorder
CA2553670A1 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
DK1720540T3 (da) 2004-02-18 2008-10-06 Gpc Biotech Ag Satraplatin til behandling af resistente tumorer eller tumorer, der er vanskelige at behandle
WO2006002119A2 (en) 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
EP1824831A2 (de) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
CA2600154A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fluorescence polarization assays for acetyltransferase/deacetylase activity
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
BRPI0613429A2 (pt) * 2005-07-14 2009-02-10 Takeda San Diego Inc inibidores de histona desacetilase
ES2389111T3 (es) * 2005-12-02 2012-10-23 Sirtris Pharmaceuticals, Inc. Ensayos de espectrometría de masas para la actividad acetiltransferasa/desacetilasa
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8518635B2 (en) * 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation
WO2009026234A1 (en) * 2007-08-17 2009-02-26 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
GB0909912D0 (en) 2009-06-09 2009-07-22 Univ Dundee Compounds
ES2596953T3 (es) 2010-02-02 2017-01-13 Allos Therapeutics, Inc. Diastereómeros de 10-propargil-10-desazaaminopterina para uso en el tratamiento del cáncer de pulmón
US9290791B2 (en) 2010-05-18 2016-03-22 Cornell University Reagents and methods for sirtuin capture
JP5947623B2 (ja) * 2012-06-04 2016-07-06 インフォコム株式会社 抗がん剤の効果増強剤
FR3086493B1 (fr) * 2018-09-20 2020-08-28 Renault Sas Procede de reattribution d’un serveur peripherique de traitement de donnees
WO2024158914A1 (en) * 2023-01-24 2024-08-02 Beth Israel Deaconess Medical Center, Inc. Optical sensor probes

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8800276D0 (en) 1988-01-07 1988-02-10 Univ Liverpool Medical treatment
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
TW197439B (de) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
AU7623194A (en) 1993-09-03 1995-03-22 Vpi Holdings Ltd. Oligonucleotides with rna cleavage activity
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
AU706417B2 (en) 1994-02-23 1998-06-17 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
WO1998013059A1 (en) 1996-09-27 1998-04-02 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
WO1998022451A1 (fr) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Derives taxol
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
WO1998058927A1 (en) 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
JP4153660B2 (ja) 1997-10-08 2008-09-24 株式会社横浜国際バイオ研究所 タキソイド誘導体およびその製造方法
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
EP1529115A4 (de) * 2001-07-06 2005-08-24 Elixir Pharmaceuticals Inc Sir2-aktivität
WO2003046207A2 (en) * 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity

Also Published As

Publication number Publication date
US7884081B2 (en) 2011-02-08
CA2485988C (en) 2013-12-24
US20040028607A1 (en) 2004-02-12
US7351542B2 (en) 2008-04-01
AU2003229329A1 (en) 2003-12-12
EP1514105A2 (de) 2005-03-16
CA2485988A1 (en) 2003-12-04
AU2003229329B2 (en) 2009-08-06
EP1982720A1 (de) 2008-10-22
US20090005328A1 (en) 2009-01-01
WO2003099210A2 (en) 2003-12-04
ATE412771T1 (de) 2008-11-15
WO2003099210A3 (en) 2004-03-18
EP1514105A4 (de) 2006-05-17
ES2318131T3 (es) 2009-05-01
EP1514105B1 (de) 2008-10-29

Similar Documents

Publication Publication Date Title
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
ATE531365T1 (de) Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
MXPA05008649A (es) Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
NO20006007D0 (no) Fremgangsmåte til dosering av et medikament, samt doseringsform
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
DE602004025726D1 (de) Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
NO20045056L (no) Fremgangsmater for behandling av hepatitt
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
PT998287E (pt) Utilizacao de levobupivacaina
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
ATE545423T1 (de) Mittel zur behandlung von lungenkrebs
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition